Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Support Care Cancer ; 21(2): 511-9, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22842921

RESUMO

PURPOSE: A prospective cohort study was conducted to analyze whether self-reported fatigue predicts overall survival in patients with esophageal cancer. METHODS: Patients enrolled in the Mayo Clinic Esophageal Adenocarcinoma and Barrett's Esophagus Registry between September 2001 and January 2009 who completed a baseline quality of life instrument were eligible for evaluation. The fatigue component was scored on a 0-10 scale, with 0 as extreme fatigue. Patients were categorized as having a decreased energy level if they reported a score of ≤ 5. Fatigue scores ≥ 6 reflect normal levels of energy. RESULTS: Data from a total of 659 enrolled patients were analyzed. A total of 392 (59 %) and 267 (41 %) patients reported decreased and normal energy, respectively. Univariate analysis indicates patients with normal energy had improved 5-year survival compared to patients with decreased energy (37 vs 28 %, hazard ratio (HR) 0.74, p = 0.006). Among the patients with locally advanced disease, the same relationship was seen (28 vs 17 %, HR = 0.67, p = 0.003); this remained significant on multivariate analysis (HR = 0.71, p = 0.015). CONCLUSIONS: A decreased energy level is associated with poor survival in patients with esophageal cancer. Thus, patients with high levels of fatigue should be referred for psychological support and be considered for therapy aimed at amelioration of fatigue symptoms.


Assuntos
Esôfago de Barrett/complicações , Neoplasias Esofágicas/complicações , Fadiga/etiologia , Qualidade de Vida , Adenocarcinoma/complicações , Adenocarcinoma/mortalidade , Adenocarcinoma/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Esôfago de Barrett/mortalidade , Esôfago de Barrett/patologia , Carcinoma de Células Escamosas/complicações , Carcinoma de Células Escamosas/mortalidade , Carcinoma de Células Escamosas/patologia , Neoplasias Esofágicas/mortalidade , Neoplasias Esofágicas/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Prospectivos , Sistema de Registros , Perfil de Impacto da Doença , Análise de Sobrevida , Adulto Jovem
2.
J Clin Microbiol ; 35(3): 631-5, 1997 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-9041402

RESUMO

Virologic measurements are becoming important surrogate markers for therapeutic efficacy in clinical trials with human immunodeficiency virus (HIV)-infected subjects. One such marker which is inexpensive and easily evaluated is the HIV p-24 antigen. To determine the storage stability of p24 antigen assayed by enzyme-linked immunosorbent assay of serum collected during clinical trials, a retrospective analysis was performed. The p24 antigen results were available from four Adult or Pediatric AIDS Clinical Trials Group protocols: studies 047, 050, 128, and 213. Paired samples (n = 930) which were assayed by ELISA for p24 antigen both in real time and in batch were analyzed for agreement. Batch and real-time values were correlated; however, there was a lack of agreement which increased with prolonged storage time of batched samples and greater p24 antigen levels. The p24 antigen values were significantly lower in the batched samples, which had a maximum storage time of 1,548 days. The degradation rate of p24 antigen per year was 0.052 log10 for samples with less than 30 pg/ml, 0.197 log10 for those with 30 to 100 pg/ml, and 0.245 log10 for those with > 100 pg/ml. Due to degradation over time, use of p24 antigen values from batch assays with long-term storage could bias study results toward a lack of treatment effect. On the basis of these results we make the following recommendations. (i) Samples should be assayed either in real time by laboratories undergoing quality assurance or in batch with short-term storage (less than 1 year). (ii) When real-time assays are to be performed, the serum samples should not be stored at 4 degrees C, but should be frozen immediately after processing and stored frozen until tested.


Assuntos
Proteína do Núcleo p24 do HIV/sangue , Adulto , Fármacos Anti-HIV/uso terapêutico , Biomarcadores/sangue , Preservação de Sangue , Criança , Protocolos Clínicos , Ensaios Clínicos como Assunto , Ensaio de Imunoadsorção Enzimática , Congelamento , Infecções por HIV/tratamento farmacológico , Infecções por HIV/virologia , Humanos , Prognóstico , Estudos Retrospectivos , Fatores de Tempo , Virologia/métodos
3.
J Exp Med ; 134(2): 439-57, 1971 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-4104425

RESUMO

The immunochemical properties of purified A(1) and A(2) glycoproteins have been compared to ascertain whether their antigenic determinants differ. Quantitative precipitin and complement-fixation studies using several anti-A sera as well as purified gammaG anti-A antibodies clearly showed a specificity difference. This was also supported by absorption studies: A(2) substance specifically removed antibodies reacting with A(2) substance leaving anti-A(1) activity. A(1) substance was more effective than A(2) substance in dissolving an A(1) anti-A(1)-specific precipitate. Purified gammaM anti-A hemolyzed A(1) cells more readily than A(2) cells. Inhibition studies using mono- and difucosyl type 2 A-active oligosaccharides showed that type 2 difucosyl receptors are present in A(2) substance. The structural basis for the specificity difference between A(1) and A(2) would appear to be that A(2) substances lack type 1 A determinants; this would account for the observed higher H and Le(b) activity in A(2) substances.


Assuntos
Sistema ABO de Grupos Sanguíneos , Anticorpos , Antígenos , Glicoproteínas , Animais , Especificidade de Anticorpos , Sítios de Ligação , Testes de Fixação de Complemento , Epitopos , Eritrócitos/imunologia , Testes de Inibição da Hemaglutinação , Testes de Hemaglutinação , Humanos , Oligossacarídeos , Suínos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA